Acasti Pharma Inc. [NASDAQ: ACST] traded at a high on 05/07/21, posting a 16.49 gain after which it closed the day’ session at $0.47. The company report on May 7, 2021 that Acasti Pharma Merger Investigation: Halper Sadeh LLP Announces Investigation Into Whether the Merger of Acasti Pharma Inc. Is Fair to Shareholders; Investors Are Encouraged to Contact the Firm – ACST.
Halper Sadeh LLP, a global investor rights law firm, is investigating whether the merger of Acasti Pharma Inc. (NASDAQ: ACST) and Grace Therapeutics Inc. is fair to Acasti shareholders. Under the merger, Grace stockholders will receive newly issued Acasti common shares. Upon closing, Acasti securityholders are expected to own approximately 55% of the combined company’s common shares on a pro forma basis, subject to certain adjustments.
Halper Sadeh encourages Acasti shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or firstname.lastname@example.org or email@example.com.
The results of the trading session contributed to over 95992457 shares changing hands. Over the past one week, the price volatility of Acasti Pharma Inc. stands at 13.41% while the volatility over the past one month is 11.31%.
The market cap for ACST stock reached $94.42 million, with 200.12 million shares outstanding and 179.14 million shares in the current float. Compared to the average trading volume of 20.45M shares, ACST reached a trading volume of 95992457 in the most recent trading day, which is why market watchdogs consider the stock to be active.
What do top market gurus say about Acasti Pharma Inc. [ACST]?
Oppenheimer have made an estimate for Acasti Pharma Inc. shares, keeping their opinion on the stock as Perform, with their previous recommendation back on September 01, 2020. The new note on the price target was released on July 06, 2020, representing the official price target for Acasti Pharma Inc. stock.
The Average True Range (ATR) for Acasti Pharma Inc. is set at 0.06, with the Price to Sales ratio for ACST stock in the period of the last 12 months amounting to 1165.64. The Price to Book ratio for the last quarter was 2.86.
How has ACST stock performed recently?
Acasti Pharma Inc. [ACST] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -4.30. With this latest performance, ACST shares dropped by -14.93% in over the last four-week period, additionally plugging by 148.97% over the last 6 months – not to mention a drop of -25.97% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for ACST stock in for the last two-week period is set at 45.49, with the RSI for the last a single of trading hit 49.00, and the three-weeks RSI is set at 44.57 for Acasti Pharma Inc. [ACST]. The present Moving Average for the last 50 days of trading for this stock 0.5729, while it was recorded at 0.4426 for the last single week of trading, and 0.4833 for the last 200 days.
Acasti Pharma Inc. [ACST]: Deeper insight into the fundamentals
Return on Total Capital for ACST is now -198.39, given the latest momentum, and Return on Invested Capital for the company is -216.98. Return on Equity for this stock declined to -217.64, with Return on Assets sitting at -86.29. When it comes to the capital structure of this company, Acasti Pharma Inc. [ACST] has a Total Debt to Total Equity ratio set at 1.13. Additionally, ACST Total Debt to Total Capital is recorded at 1.12, with Total Debt to Total Assets ending up at 0.64. Long-Term Debt to Equity for the company is recorded at 0.55, with the Long-Term Debt to Total Capital now at 0.54.
Insider trade positions for Acasti Pharma Inc. [ACST]
There are presently around $2 million, or 2.21% of ACST stock, in the hands of institutional investors. The top three institutional holders of ACST stocks are: RENAISSANCE TECHNOLOGIES LLC with ownership of 1,924,000, which is approximately New of the company’s market cap and around 2.70% of the total institutional ownership; VIRTU FINANCIAL LLC, holding 687,985 shares of the stock with an approximate value of $0.28 million in ACST stocks shares; and TWO SIGMA ADVISERS, LP, currently with $0.12 million in ACST stock with ownership of nearly 1.022% of the company’s market capitalization.
Positions in Acasti Pharma Inc. stocks held by institutional investors increased at the end of June and at the time of the June reporting period, where 14 institutional holders increased their position in Acasti Pharma Inc. [NASDAQ:ACST] by around 3,053,296 shares. Additionally, 7 investors decreased positions by around 136,702 shares, while 11 investors held positions by with 971,621 shares. The mentioned changes placed institutional holdings at 4,161,619 shares, according to the latest SEC report filing. ACST stock had 9 new institutional investments in for a total of 2,352,806 shares, while 6 institutional investors sold positions of 134,702 shares during the same period.